

## **IN THE CLAIMS**

1. (currently amended) An extruded composition comprising:  
a core which comprises
  - a. a carrier, and
  - b. at least one aminoketone antidepressant,said extruded composition providing an *in vivo* plasma profile selected from:
  - a. a  $C_{\max}$  of at least 50.0 ng/ml;
  - b. an  $AUC_{0-\infty}$  of greater than approximately 500.0 ng·hr/ml; and
  - c. a  $T_{\max}$  of between approximately 5.0 hours and 8.5 hours.
2. (original) The composition of claim 1 wherein said core further comprises at least one binder.
3. (original) The composition of claim 2 wherein said binder comprises hydroxypropyl methylcellulose.
4. (original) The composition of claim 1 further comprising at least one polymer for controlled release delivery of said aminoketone antidepressant.
5. (original) The composition of claim 4 wherein said polymer is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, cellulose acetate, cellulose

acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, polyvinyl acetate phthalate and mixtures thereof.

6. (original) The composition of claim 4 wherein said polymer is water insoluble.

7. (withdrawn) The composition of claim 6 wherein said water insoluble polymer comprises a methacrylic acid copolymer.

8. (original) The composition of claim 6 wherein said water insoluble polymer comprises ethylcellulose.

9. (original) The composition of claim 4 wherein said polymer is insoluble below about pH 7.

10. (previously presented) The composition of claim 4 wherein said composition has a coating comprising a polymer.

11. (previously presented) An extruded dosage form comprising at least one composition of claim 1.

12. (original) The dosage form of claim 11 wherein said composition further comprises at least one binder.

13. (original) The dosage form of claim 12 wherein said binder is hydroxypropyl methylcellulose.

14. (original) The dosage form of claim 11 further comprising at least one polymer for controlled release delivery.

15. (original) The dosage form of claim 14 wherein said polymer is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, polyvinyl acetate phthalate and mixtures thereof.

16. (original) The dosage form of claim 15 wherein said polymer is water insoluble.

17. (previously presented) The dosage form of claim 16 wherein said water insoluble polymer comprises ethylcellulose.

18. (original) The dosage form of claim 14 wherein said polymer is insoluble below about pH 7.

19. (original) The dosage form of claim 14 wherein said dosage form is for once daily administration.

20. (previously presented) The dosage form of claim 11 wherein said dosage form is a tablet, caplet, capsule or extruded tablet.

21. (original) The dosage form of claim 11 comprising at least two distinct compositions of claim 1.

22. (original) The dosage form of claim 21 wherein at least one distinct composition is for controlled release.

23-28. (canceled)

29. (withdrawn) A pellet comprising:

- a. a core comprising (1) an inert carrier; having (2) bupropion, its salts or isomers, or a pharmaceutically acceptable aminoketone antidepressant agent; and (3) a binder; and

- b. a coating comprising a pH dependent coating agent selected from the group consisting of hydroxypropyl methylcellulose phthalate and a methacrylic acid copolymer.

30. (withdrawn) A pellet comprising:

- a. a core comprising (1) an inert carrier; (2) bupropion, its salts or isomers, or a pharmaceutically acceptable aminoketone antidepressant agent; and (3) a binder; and
- b. a coating composition comprising a methacrylic acid copolymer and a water insoluble polymer.

31. (withdrawn) A dosage form of claim 11, said dosage form comprising a first pellet having a coating comprising methacrylic acid copolymer and a second pellet having a coating comprising methacrylic acid copolymer.

32. (withdrawn) The dosage form of claim 31 wherein said methacrylic acid copolymer of said first pellet is pH independent.

33. (withdrawn) The dosage form of claim 31 wherein said methacrylic acid copolymer of said second pellet is pH independent.

34-37. (canceled)

38. (withdrawn) A pelletized composition comprising:  
a core which comprises
- i. an inert carrier, having
  - ii. at least one aminoketone antidepressant layered thereon.
39. (withdrawn) The composition of claim 38 wherein said core further comprises at least one binder.
40. (withdrawn) The composition of claim 39 wherein said binder comprises hydroxypropyl methylcellulose.
41. (withdrawn) composition of claim 38 further comprising at least one polymer for controlled release delivery of said aminoketone antidepressant.
42. (withdrawn) The composition of claim 41 wherein said polymer is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, polyvinyl acetate phthalate and mixtures thereof.
43. (withdrawn) The composition of claim 41 wherein said polymer is water insoluble.

44. (withdrawn) The composition of claim 42 wherein said water insoluble polymer comprises ethylcellulose.

45. (withdrawn) The composition of claim 41 wherein said polymer is insoluble below about pH 7.

46. (withdrawn) The composition of claim 41 wherein said composition has a coating comprising a polymer.

47. (withdrawn) A pelletized dosage form comprising at least one composition of claim 38.

48. (withdrawn) The dosage form of claim 47 wherein said composition further comprises at least one binder.

49. (withdrawn) The dosage form of claim 48 wherein said binder is hydroxypropyl methylcellulose.

50. (withdrawn) The dosage form of claim 49 further comprising at least one polymer for controlled release delivery.

51. (withdrawn) The dosage form of claim 50 wherein said polymer is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, polyvinyl acetate phthalate and mixtures thereof.

52. (withdrawn) The dosage form of claim 51 wherein said polymer is water insoluble.

53. (withdrawn) The dosage form of claim 51 wherein said water insoluble polymer comprises ethylcellulose.

54. (withdrawn) The dosage form of claim 50 wherein said polymer is insoluble below about pH 7.

55. (withdrawn) The dosage form of claim 50 wherein said dosage form is for once daily administration.

56. (withdrawn) The dosage form of claim 47 wherein said dosage form is a tablet, caplet, capsule or palletized tablet.



57. (withdrawn) The dosage form of claim 47 comprising at least two distinct compositions of claim 38.

58. (withdrawn) The dosage form of claim 57 wherein at least one distinct composition is for controlled release.

59. (withdrawn) A dosage form of claim 47, said dosage form comprising a first pellet having a coating comprising methacrylic acid copolymer and a second pellet having a coating comprising methacrylic acid copolymer.

60. (withdrawn) The dosage form of claim 59 wherein said methacrylic acid copolymer of said first pellet is pH independent.

61. (withdrawn) The dosage form of claim 59 wherein said methacrylic acid copolymer of said second pellet is pH independent.